Search results for "HB"

showing 10 items of 1066 documents

Hepatitis B virus markers among family contacts of asymptomatic HBsAg carriers.

1979

A study was undertaken to establish the risk of family contacts of HBsAg carriers acquiring a hepatitis B virus (HBV) infection. About one-third of all household contacts of asymptomatic HBsAg carriers had signs of past or ongoing HBV infection. Family contacts of HBsAg carriers with high numbers of circulating Dane particles were shown to have a higher risk of developing HBV infection than family contacts of HBsAg carriers without serological evidence of HBV synthesis. The probability of acquiring HBV infection was not different between spouses, parents, children, and brothers and sisters, respectively of asymptomatic HBsAg carriers.

AdultMaleHepatitis B virusRadioimmunoassaySerological evidenceFluorescent Antibody TechniqueDNA-Directed DNA Polymerasemedicine.disease_causeHepatitis b surface antigenAsymptomaticHepatitis B AntigensmedicineHumansChildHepatitis B virusHepatitis B Surface Antigensbusiness.industryCarrier stateGastroenterologyvirus diseasesHepatitis Bmedicine.diseaseHepatitis BVirologydigestive system diseasesLiverImmunologyCarrier StateHbsag carrierFemalemedicine.symptombusinessLiver pathologyScandinavian journal of gastroenterology
researchProduct

No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study.

2013

OBJECTIVES: The widespread use of tumour necrosis factor (TNF)-targeted therapies in patients with rheumatic, digestive and dermatologic diseases has been associated with reports of reactivation of HBV replication and ensuing hepatitis flares both in asymptomatic HBsAg carriers and in subjects with occult HBV infection. The aim of our work was to investigate in a two-year prospective study the potential for HBV reactivation in patients with inflammatory joint diseases undergoing anti-TNF treatment from a southern Mediterranean area. METHODS: Fifty-seven consecutive outpatients attending the Academic Unit of Rheumatology at the University of Palermo (12 with rheumatoid arthritis, 17 with pso…

AdultMaleHepatitis B virusTime Factorsoccult HBV-DNAAntiviral AgentsPolymerase Chain ReactionRisk AssessmentRisk FactorsRheumatic Diseasesoccult HBV-DNA rheumatic diseases anti-TNFHumansProspective Studiesrheumatic diseaseAcademic Medical CentersHepatitis B Surface AntigensTumor Necrosis Factor-alphavirus diseasesanti-TNFMiddle AgedHepatitis Bdigestive system diseasesTreatment OutcomeItalyLamivudineAntirheumatic AgentsDNA ViralFemaleVirus ActivationBiomarkers
researchProduct

Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: The EPIB 2008 study

2010

To compare the management and the virological and serological efficacy of treatments for chronic hepatitis B (CHB) in HIV positive and negative patients.Two hundred and forty-six HIV positive and 205 HIV negative consecutive patients with past or present CHB, seen in October 2008 in participating departments, were included in a multicenter study. All the data were retrospectively collected from the first visit to October 2008 through a standardized questionnaire.Compared to HIV negative patients, HIV positive patients more often presented positive HBeAg (46.4% vs. 32.8%, p=0.01), HBV genotype A (54.8% vs. 17.1%, p0.0001), co-infection with HCV (12.4% vs. 5.9%, p=0.0002) or HDV (12.6% vs. 2.…

AdultMaleHepatitis B virusmedicine.medical_specialtyOrganophosphonatesHIV InfectionsAntiviral AgentsSerologyHepatitis B AntigensHepatitis B ChronicPharmacotherapyAcquired immunodeficiency syndrome (AIDS)Surveys and QuestionnairesInternal medicinemedicineHumansHepatitis B AntibodiesTenofovirSidaRetrospective StudiesHepatologybiologybusiness.industryAdeninevirus diseasesMiddle AgedHepatitis Bbiology.organism_classificationmedicine.diseaseHBeAgLentivirusImmunologyFemaleFranceViral diseasebusinessJournal of Hepatology
researchProduct

Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C

2003

Occult HBV infection in subjects with chronic hepatitis C is related to more severe disease outcome. It has been suggested that it might reduce sensitivity to antiviral treatment.To assess in HBsAg negative subjects with chronic hepatitis C any effect of the presence of HBV genomes in the liver on the early kinetics of HCV-RNA under PEG-IFN plus ribavirin.Twenty-two anti-HCV and HCV-RNA positive subjects, with biopsy-proven chronic hepatitis C (M/F 15/7; 50 +/- 8.6 years, 16 genotype 1b) were given PEG-IFN alpha 2b 1.0 microg qw plus ribavirin (800 to 1,200 mg daily according to body weight) for an intended 52 week period. Early virological response was assessed over the first 4 weeks of th…

AdultMaleHepatitis B viruspegylated interferon-alphaGenotypeBiopsyHepacivirusInterferon alpha-2Virus ReplicationAntiviral AgentsPolyethylene GlycolsHepatitis B AntibodieRibavirinchronic hepatitis CHumansHepatitis B AntibodiesAntiviral AgentHepaciviruoccult HBV infection; chronic hepatitis C; pegylated interferon-alpha; viral dynamics; treatment responseoccult HBV infectiontreatment responseInterferon-alphaAlanine TransaminaseHepatitis B viruHepatitis C AntibodiesHepatitis C ChronicMiddle AgedRecombinant ProteinViral LoadHepatitis Bviral dynamicsRecombinant ProteinsTreatment OutcomeLiverDNA ViralRNA ViralDrug Therapy CombinationFemaleHepatitis C AntibodieHuman
researchProduct

Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Stu…

2016

International audience;  Although an isolated anti-hepatitis B virus (HBV) core antibody (anti-HBc) serological profile is frequent in human immunodeficiency virus (HIV)-infected patients, data on HBV vaccination in these patients are scarce.  A prospective multicenter study was conducted to assess the immunogenicity of HBV vaccination in 54 patients with an isolated anti-HBc profile and undetectable HIV load. They were vaccinated with 1 dose (20 µg) of recombinant HBV vaccine. Those with an anti-HBV surface antibody (anti-HBs) level of 100 mIU/mL 4 weeks after a single recall dose of HBV vaccine should be further vaccinated with a reinforced triple double-dose scheme.

AdultMaleHuman immunodeficiency virus (HIV)HIV Infectionsmedicine.disease_causeVirusSerology03 medical and health sciences0302 clinical medicineImmunogenicity Vaccine[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyAntiretroviral Therapy Highly ActiveHepatitis B virus HBVImmunology and AllergyMedicineHumansHepatitis B Vaccines030212 general & internal medicineProspective StudiesHepatitis B AntibodiesProspective cohort study[SDV.MP] Life Sciences [q-bio]/Microbiology and ParasitologyVaccines Syntheticbiologybusiness.industryImmunogenicityvirus diseasesMiddle AgedHepatitis BVirologyHepatitis B Core Antigensdigestive system diseasesVaccinationInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyImmunologybiology.proteinHIV-1030211 gastroenterology & hepatologyFemaleAntibodybusiness
researchProduct

Prevalence of Occult Hepatitis B Virus Infection in a Cohort of HIV-Positive Patients Resident in Sicily, Italy

2013

Occult hepatitis B virus (OBI) in HIV-infected groups is still debated, as well as the associated risk-factors and clinical significance. In this paper, we examined a total of 405 HBsAg-negative/HIV-infected patients enrolled from January 2007 to December 2009. Overall, the prevalence of OBI was 5.9% (95% confidence interval (CI95%): 3.8–8.7%); it was more frequently associated with “anti-HBc alone” serological marker (11.3%; adjusted odds ratio = 3.7, CI95%: 1.4–9.8), although it was also detected in the absence of any HBV serological marker (4.9%; CI95%: 2.3–9.1%). A low prevalence of anti-HCV-positive patients with OBI was found (3.1%; CI95%: 0.6–8.7%). HIV RNA plasma levels or other imm…

AdultMaleOccult HBV HIV Prevalence Sicily Italymedicine.medical_specialtyHepatitis B virusArticle Subjectlcsh:MedicineHIV Infectionsmedicine.disease_causeSettore MED/42 - Igiene Generale E ApplicataGeneral Biochemistry Genetics and Molecular BiologySerologyInternal medicineGenotypemedicinePrevalenceHumansClinical significanceSicilyDemographyHepatitis B virusHepatitis B Surface AntigensGeneral Immunology and Microbiologybusiness.industrylcsh:Rvirus diseasesGeneral MedicineOdds ratioHepatitis Bmedicine.diseaseHepatitis BOccultdigestive system diseasesCohortImmunologyClinical StudyFemalebusiness
researchProduct

Malignant paraganglioma caused by a novel germline mutation of the succinate dehydrogenase D-gene--a case report.

2008

Background Paragangliomas of the head and neck are rare, mostly benign tumors. Approximately 10% to 15% of paragangliomas are caused by mutations in the succinate dehydrogenase (SDH) genes B, C, or D. These are often multifocal as part of paraganglioma syndromes and hormone secreting, and malignant particularly associated with mutations in SDHB. Methods and Results A 29-year-old man was seen with recurrent paraganglioma. The patient's father reportedly suffered from bilateral carotid body tumors. Imaging studies showed metastases in both lungs and the liver. There was no increased hormone production by the tumor. Sequence analysis of the SDH genes revealed a novel C to T nonsense mutation i…

AdultMalePathologymedicine.medical_specialtySDHBNonsense mutationmedicine.disease_causeRisk AssessmentSkull Base NeoplasmsPheochromocytomaParagangliomaTreatment RefusalGermline mutationParagangliomamedicineMalignant ParagangliomaHumansGenetic Predisposition to DiseaseGerm-Line MutationNeoplasm StagingMutationbusiness.industryBiopsy Needlemedicine.diseaseImmunohistochemistryPedigreeSuccinate DehydrogenaseOtorhinolaryngologyPositron-Emission TomographySDHDbusinessHeadneck
researchProduct

SDHB Expression in Warthin's Tumour

2011

Abstract Introduction Succinic dehydrogenase subunit B (SDHB) is an enzyme belonging to the mitochondrial complex II. The aim of this study is to analyse SDHB expression in a series of Warthin's tumours, studying its relationship with oncocytic changes, constantly present in this form of tumour. Material and methods In resection tumour specimens from a series of ten Warthin's tumours (all from the parotid gland), immunohistochemical expression of SDHB was analysed using a commercially available monoclonal antibody. Results The Warthin's tumours studied affected 10 men (mean age: 64.2 yrs, range 40–80), all with smoking habits, and 2 with metachronous bilateral involvement. Two patients pres…

AdultMalePathologymedicine.medical_specialtySmoking habitSDHBWarthin's tumourmedicineHumansAdenolymphomaAgedAged 80 and overbusiness.industryStriated ductGeneral MedicineMiddle AgedAdenolymphomamedicine.diseaseSquamous metaplasiaParotid NeoplasmsParotid glandSuccinate Dehydrogenasestomatognathic diseasesmedicine.anatomical_structureImmunohistochemistrybusinessActa Otorrinolaringologica (English Edition)
researchProduct

Diabetes mellitus prevalence and control in sleep-disordered breathing: The European Sleep Apnea Cohort (ESADA) study

2014

BACKGROUND: OSA is associated with an increased risk of cardiovascular morbidity. A driver of this is metabolic dysfunction and in particular type 2 diabetes mellitus (T2DM). Prior studies identifying a link between OSA and T2DM have excluded subjects with undiagnosed T2DM, and there is a lack of population-level data on the interaction between OSA and glycemic control among patients with diabetes. We assessed the relationship between OSA severity and T2DM prevalence and control in a large multinational population.METHODS: We performed a cross-sectional analysis of 6,616 participants in the European Sleep Apnea Cohort (ESADA) study, using multivariate regression analysis to assess T2DM prev…

AdultMalePulmonary and Respiratory MedicineAdolescentPolysomnographySettore MED/10 - Malattie Dell'Apparato RespiratorioCritical Care and Intensive Care MedicineSeverity of Illness IndexRegression AnalysiCohort Studiesintermittent hypoxia insulin resistance HbA1CYoung AdultSleep Apnea SyndromesSleep Apnea SyndromeRisk FactorsPrevalenceHumansProspective StudiesIsraelAgedGlycated HemoglobinAged 80 and overCross-Sectional StudieHemoglobin A GlycosylatedRisk FactorMiddle AgedEuropeProspective StudieCross-Sectional StudiesDiabetes Mellitus Type 2Regression AnalysisFemaleCohort StudieCardiology and Cardiovascular MedicineHuman
researchProduct

Detection of gamma-hydroxybutyrate in hair: Validation of GC–MS and LC–MS/MS methods and application to a real case

2012

A gas chromatography-mass spectrometry (GC-MS) and a liquid chromatography tandem mass spectrometry (LC-MS/MS) method were validated for quantifying endogenous and exogenous hair concentrations of gamma-hydroxybutyrate (GHB). The GC-MS method is based on overnight extraction of 25 mg hair in NaOH at 56 °C, liquid/liquid extraction in ethylacetate and trimethylsylil derivatization; analysis is by electron ionization and single ion monitoring of three ions. The LC-MS/MS method entails a rapid digestion of 25 mg hair with NaOH at 75 °C for 40 min, liquid/liquid extraction in ethylacetate and reconstitution of the extract in the LC mobile phase; negative ion electrospray ionization and multiple…

AdultMaleQuality ControlSpectrometry Mass Electrospray IonizationSubstance-Related DisordersElectrospray ionizationClinical BiochemistryLiquid-Liquid ExtractionPharmaceutical ScienceAcetatesTandem mass spectrometryMass spectrometryGas Chromatography-Mass SpectrometryAnalytical ChemistryForensic ToxicologySettore MED/43 - Medicina LegaleLiquid chromatography–mass spectrometryLimit of DetectionTandem Mass SpectrometryDrug DiscoveryHumansSodium HydroxideSpectroscopyDetection limitChromatographyChemistryIllicit DrugsSelected reaction monitoringHair Segmental analysis GC–MS LC–MS/MSTemperatureReproducibility of ResultsGamma hydroxybutyrateReference StandardsSubstance Abuse DetectionGamma-hydroxybutyrate GHBCalibrationLinear ModelsCrimeGas chromatography–mass spectrometrySodium OxybateChromatography LiquidHair
researchProduct